Tuhura Biosciences publishes corporate deck on strategies to overcome cancer immunotherapy resistance
Reuters2026/08/12 15:42- Tuhura Biosciences highlighted a Phase 3 accelerated-approval study of IFx-2.0 in first-line metastatic Merkel cell carcinoma.
- Trial targets about 118 patients, with topline data expected in 2H 2027; design uses ORR primary endpoint, PFS key secondary.
- Program runs under an FDA Special Protocol Assessment; confirmatory trial not expected to be required.
- Tuhura plans to start a Phase 1b/2 trial of VISTA-inhibiting antibody TBS-2025 in mutNPM1 relapsed or refractory AML in 2H 2026.
- Company cited a $50 million credit facility and royalty transaction, projecting operating runway through Q1 2028.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Data: The current Crypto Fear & Greed Index is 68, indicating a state of greed.
The global autonomous driving battle intensifies! Alphabet's Waymo teams up with a Japanese giant to seize the Tokyo market.
Waymo, a subsidiary of Alphabet, announced a partnership with a major Japanese taxi company to launch autonomous driving services in Tokyo in 2027. Following the news, shares of its partner, Go, surged by 9.7%.
Treasury Firms Stack Ethereum, Solana, and Bitcoin Through a Jittery September Market
UOB Kay Hian: Maintains "Buy" rating for Waterdrop (WDH.US), raises target price to $2.23
Based on revised profit forecasts, UOB Kay Hian has maintained its “Buy” rating on Waterdrop and raised the target price to $2.23.
Crypto prices
More
